226 related articles for article (PubMed ID: 15994801)
1. The V1, V2, and V3 regions of the human immunodeficiency virus type 1 envelope differentially affect the viral phenotype in an isolate-dependent manner.
Saunders CJ; McCaffrey RA; Zharkikh I; Kraft Z; Malenbaum SE; Burke B; Cheng-Mayer C; Stamatatos L
J Virol; 2005 Jul; 79(14):9069-80. PubMed ID: 15994801
[TBL] [Abstract][Full Text] [Related]
2. V2 loop glycosylation of the human immunodeficiency virus type 1 SF162 envelope facilitates interaction of this protein with CD4 and CCR5 receptors and protects the virus from neutralization by anti-V3 loop and anti-CD4 binding site antibodies.
Ly A; Stamatatos L
J Virol; 2000 Aug; 74(15):6769-76. PubMed ID: 10888615
[TBL] [Abstract][Full Text] [Related]
3. Effect of major deletions in the V1 and V2 loops of a macrophage-tropic HIV type 1 isolate on viral envelope structure, cell entry, and replication.
Stamatatos L; Wiskerchen M; Cheng-Mayer C
AIDS Res Hum Retroviruses; 1998 Sep; 14(13):1129-39. PubMed ID: 9737584
[TBL] [Abstract][Full Text] [Related]
4. An envelope modification that renders a primary, neutralization-resistant clade B human immunodeficiency virus type 1 isolate highly susceptible to neutralization by sera from other clades.
Stamatatos L; Cheng-Mayer C
J Virol; 1998 Oct; 72(10):7840-5. PubMed ID: 9733820
[TBL] [Abstract][Full Text] [Related]
5. Human immunodeficiency virus type 1 V1-V2 envelope loop sequences expand and add glycosylation sites over the course of infection, and these modifications affect antibody neutralization sensitivity.
Sagar M; Wu X; Lee S; Overbaugh J
J Virol; 2006 Oct; 80(19):9586-98. PubMed ID: 16973562
[TBL] [Abstract][Full Text] [Related]
6. Changes in the immunogenic properties of soluble gp140 human immunodeficiency virus envelope constructs upon partial deletion of the second hypervariable region.
Srivastava IK; VanDorsten K; Vojtech L; Barnett SW; Stamatatos L
J Virol; 2003 Feb; 77(4):2310-20. PubMed ID: 12551968
[TBL] [Abstract][Full Text] [Related]
7. N-linked glycosylation of the V3 loop and the immunologically silent face of gp120 protects human immunodeficiency virus type 1 SF162 from neutralization by anti-gp120 and anti-gp41 antibodies.
McCaffrey RA; Saunders C; Hensel M; Stamatatos L
J Virol; 2004 Apr; 78(7):3279-95. PubMed ID: 15016849
[TBL] [Abstract][Full Text] [Related]
8. Assorted mutations in the envelope gene of simian immunodeficiency virus lead to loss of neutralization resistance against antibodies representing a broad spectrum of specificities.
Johnson WE; Sanford H; Schwall L; Burton DR; Parren PW; Robinson JE; Desrosiers RC
J Virol; 2003 Sep; 77(18):9993-10003. PubMed ID: 12941910
[TBL] [Abstract][Full Text] [Related]
9. Differential CD4/CCR5 utilization, gp120 conformation, and neutralization sensitivity between envelopes from a microglia-adapted human immunodeficiency virus type 1 and its parental isolate.
Martín J; LaBranche CC; González-Scarano F
J Virol; 2001 Apr; 75(8):3568-80. PubMed ID: 11264346
[TBL] [Abstract][Full Text] [Related]
10. The V1/V2 region of human immunodeficiency virus type 1 modulates the sensitivity to neutralization by soluble CD4 and cellular tropism.
Morikita T; Maeda Y; Fujii S; Matsushita S; Obaru K; Takatsuki K
AIDS Res Hum Retroviruses; 1997 Oct; 13(15):1291-9. PubMed ID: 9339846
[TBL] [Abstract][Full Text] [Related]
11. V3 loop truncations in HIV-1 envelope impart resistance to coreceptor inhibitors and enhanced sensitivity to neutralizing antibodies.
Laakso MM; Lee FH; Haggarty B; Agrawal C; Nolan KM; Biscone M; Romano J; Jordan AP; Leslie GJ; Meissner EG; Su L; Hoxie JA; Doms RW
PLoS Pathog; 2007 Aug; 3(8):e117. PubMed ID: 17722977
[TBL] [Abstract][Full Text] [Related]
12. Ability of the V3 loop of simian immunodeficiency virus to serve as a target for antibody-mediated neutralization: correlation of neutralization sensitivity, growth in macrophages, and decreased dependence on CD4.
Means RE; Matthews T; Hoxie JA; Malim MH; Kodama T; Desrosiers RC
J Virol; 2001 Apr; 75(8):3903-15. PubMed ID: 11264379
[TBL] [Abstract][Full Text] [Related]
13. Cryptic nature of a conserved, CD4-inducible V3 loop neutralization epitope in the native envelope glycoprotein oligomer of CCR5-restricted, but not CXCR4-using, primary human immunodeficiency virus type 1 strains.
Lusso P; Earl PL; Sironi F; Santoro F; Ripamonti C; Scarlatti G; Longhi R; Berger EA; Burastero SE
J Virol; 2005 Jun; 79(11):6957-68. PubMed ID: 15890935
[TBL] [Abstract][Full Text] [Related]
14. Generation and structural analysis of soluble oligomeric gp140 envelope proteins derived from neutralization-resistant and neutralization-susceptible primary HIV type 1 isolates.
Stamatatos L; Lim M; Cheng-Mayer C
AIDS Res Hum Retroviruses; 2000 Jul; 16(10):981-94. PubMed ID: 10890360
[TBL] [Abstract][Full Text] [Related]
15. Loss of a single N-linked glycan allows CD4-independent human immunodeficiency virus type 1 infection by altering the position of the gp120 V1/V2 variable loops.
Kolchinsky P; Kiprilov E; Bartley P; Rubinstein R; Sodroski J
J Virol; 2001 Apr; 75(7):3435-43. PubMed ID: 11238869
[TBL] [Abstract][Full Text] [Related]
16. Antibodies that are cross-reactive for human immunodeficiency virus type 1 clade a and clade B v3 domains are common in patient sera from Cameroon, but their neutralization activity is usually restricted by epitope masking.
Krachmarov C; Pinter A; Honnen WJ; Gorny MK; Nyambi PN; Zolla-Pazner S; Kayman SC
J Virol; 2005 Jan; 79(2):780-90. PubMed ID: 15613306
[TBL] [Abstract][Full Text] [Related]
17. A replication-competent, neutralization-sensitive variant of simian immunodeficiency virus lacking 100 amino acids of envelope.
Johnson WE; Morgan J; Reitter J; Puffer BA; Czajak S; Doms RW; Desrosiers RC
J Virol; 2002 Mar; 76(5):2075-86. PubMed ID: 11836385
[TBL] [Abstract][Full Text] [Related]
18. Replicative function and neutralization sensitivity of envelope glycoproteins from primary and T-cell line-passaged human immunodeficiency virus type 1 isolates.
Sullivan N; Sun Y; Li J; Hofmann W; Sodroski J
J Virol; 1995 Jul; 69(7):4413-22. PubMed ID: 7769703
[TBL] [Abstract][Full Text] [Related]
19. Role of low CD4 levels in the influence of human immunodeficiency virus type 1 envelope V1 and V2 regions on entry and spread in macrophages.
Walter BL; Wehrly K; Swanstrom R; Platt E; Kabat D; Chesebro B
J Virol; 2005 Apr; 79(8):4828-37. PubMed ID: 15795268
[TBL] [Abstract][Full Text] [Related]
20. Binding of antibodies to virion-associated gp120 molecules of primary-like human immunodeficiency virus type 1 (HIV-1) isolates: effect on HIV-1 infection of macrophages and peripheral blood mononuclear cells.
Stamatatos L; Zolla-Pazner S; Gorny MK; Cheng-Mayer C
Virology; 1997 Mar; 229(2):360-9. PubMed ID: 9126249
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
